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p38Perturbations in endoplasmic reticulum (ER) homeostasis, including depletion of Ca2+ or altered redox status,
induce ER stress due to protein accumulation, misfolding and oxidation. This activates the unfolded protein re-
sponse (UPR) to re-establish the balance between ER protein folding capacity and protein load, resulting in cell
survival or, following chronic ER stress, promotes cell death. Themechanisms for the transition between adapta-
tion to ER stress and ER stress-induced cell death are still being understood. However, the identiﬁcation of nu-
merous points of cross-talk between the UPR and mitogen-activated protein kinase (MAPK) signalling
pathways may contribute to our understanding of the consequences of ER stress. Indeed, the MAPK signalling
network is known to regulate cell cycle progression and cell survival or death responses following a variety of
stresses. In this article, we review UPR signalling and the activation of MAPK signalling pathways in response
to ER stress. In addition, we highlight components of the UPR that are modulated in response toMAPK signalling
and the consequences of this cross-talk. We also describe several diseases, including cancer, type II diabetes and
retinal degeneration, where activation of the UPR and MAPK signalling contribute to disease progression and
highlight potential avenues for therapeutic intervention. This article is part of a Special Issue entitled: Calcium
Signaling In Health and Disease. Guest Editors: Geert Bultynck, Jacques Haiech, Claus W. Heizmann,
Joachim Krebs, and Marc Moreau.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The endoplasmic reticulum (ER) is an extensive intracellular organ-
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ights reserved.forming an intracellular Ca2+ store that plays a central role in signal
transduction. Perturbations in the environment within the ER lumen,
for example a reduction in luminal Ca2+ concentration or altered
redox status, can affect protein folding and processing. A reduction in
folding capacity and the accumulation of misfolded proteins within
the ER activates a series of signalling pathways that are collectively
known as the ER stress response or unfolded protein response (UPR).
The UPR acts to modulate both the folding capacity and protein load
in the ER to restore homeostasis. In doing so UPR signalling acts to pro-
mote survival and adaptation to ER stress but can also promote cell
death in the event of excessive proteotoxic stimuli.
Recent research has shown that mitogen-activated protein kinase
(MAPK) signalling pathways have a role in the response to ER stress
(Fig. 1). Whilst some MAPK pathways are activated in response to ER
stress and form part of the UPR, (such as p38 and c-Jun N-terminal
kinase (JNK)), othermembersmay promote adaptation, survival and re-
sistance to ER stress (Fig. 1). In this review we introduce the core com-
ponents of the UPR andMAPK signalling pathways and then review the
interplay between these pathways, particularly as it pertains to cell sur-
vival or cell death.
2. The unfolded protein response (UPR)
UPR signalling promotes the expression of a wide range of target
genes including ER-resident chaperones [1], components of the ER-
ERK1/2 p38 JNK
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Fig. 1. Overview of MAPK signalling and points of cross-talk with the unfolded protein
response. MAPKs are activated by a three-tier signalling cascade, involving MKKKs
(blue), MKKs (green) and MAPKs (black). These MAPK signalling networks are activated
in response to extracellular signals including growth factors, cytokines and a variety of cel-
lular stresses including ER stress. Following ER stress, theUPR activatesASK1-MKK4/7-JNK
signalling and also promotes ERK1/2 activation, although the mechanism for this is
unknown. However, MEKK4-MKK3/4/6-p38 signalling also modulates the UPR via
p38-dependent phosphorylation of CHOP and ATF6.
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help cells to adapt to protein damage or misfolding or enact a cell
death response if protein damage is too severe. Three major proteins
are involved in sensing stress within the ER and activating UPRIRE1 IRE1
IRE1
a) BiP
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Fig. 2. Signalling toMAPK pathways downstream of IRE1. (a) In the absence of ER stress, IRE1 is
the ER resident chaperone BiP, which inactivates IRE1 and reduces the sensitivity of IRE1 to
activation of ERK1/2 at the ERmembrane. (b) Following ER stress, IRE1 is activated bydirect inte
of the cytosolic endoribonuclease domain of IRE1, site-speciﬁc cleavage of theXBP1mRNAand it
factor. Targets of XBP1 include the chaperone BiP, which increases protein folding capacity in
proteins, reducing the ER protein load through Regulated IRE1-Dependent Decay (RIDD
IRE1-dependent oligomerisation of TRAF2 activates ASK1-MKK4/7-JNK signalling, which can pr
urin (calcin.) ormay promote cell death. IRE1 activation also promotes activation of pro-surviva
for ERK1/2 activation has not been identiﬁed.signalling within the cytosol and other organelles; these are the trans-
membrane proteins inositol requiring protein 1 (IRE1), PKR-like ER ki-
nase (PERK) and activating transcription factor 6 (ATF6).
2.1. IRE1
The transmembrane ER stress sensor IRE1 is the most highly con-
served branch of the UPR and is the only sensor present in all eukary-
otes (Fig. 2); indeed in Saccharomyces cerevisiae IRE1 signalling is the
sole arm of the UPR. In mammalian cells there are two isoforms [3];
IRE1α is ubiquitously expressed but IRE1β is only expressed abundantly
in epithelial cells of the gastrointestinal tract [4,5]. The ER luminal do-
main of IRE1 is involved in sensing ER stress (see 2.6 below) whilst
the cytosolic endoribonuclease and kinase domains are involved in
transmitting ER stress signals to downstream effector pathways. Fol-
lowing ER stress, active IRE1 cleaves mRNAs encoding membrane and
secretory proteins that would normally be trafﬁcked through the ER, a
process termed Regulated IRE1-Dependent Decay (RIDD), and thus
contributes to a reduction in ER protein load [6,7]. This appears to in-
volve non-speciﬁc binding to mRNA. In contrast, active IRE1 cleaves x-
box binding protein 1 (XBP1) mRNA in a site-speciﬁc manner to remove
an intron, promoting its unconventional splicing [8] to generate an ac-
tive basic leucine zipper (bZIP) transcription factor (Fig. 2b) [9–12].
XBP1 targets and promotes the transcription of genes encoding ER qual-
ity control proteins such as BiP [9,13] and those involved in the ER-
associated degradation pathway [2].
The kinetics and amplitude of IRE1 signalling are regulated by a num-
ber of different proteins; for example IRE1 signalling is potentiated by
protein tyrosine phosphatase-1B, as this is required for effective activa-
tion of IRE1-dependent signalling in response to ER stress in ﬁbroblasts
[14]. Interactionwith cytosolic small heat shock proteins can also regulate
IRE1 activity; for example HSP72 promotes activation of the
endoribonuclease domain of IRE1 [15] whereas interaction with HSP90c)
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ubiquitously expressed as an inactivemonomerwithin the ERmembrane. IRE1 is bound to
ER stress inducers. Inactive IRE1 can also bind the adaptor protein Nck and this inhibits
ractionwith unfolded proteins in the ER lumenandoligomerisation; this leads to activation
s non-canonical splicing by tRNA ligase (tRNA lig.) to express the active XBP1 transcription
the ER lumen. In addition, active IRE1 cleaves mRNAs encoding membrane and secretory
). (c) ER stress also promotes the IRE1-dependent activation of JNK and ERK1/2.
omote survival through c-Jun-dependent expression of Adapt78 and inhibition of calcine-
l ERK1/2 signalling by promoting the dissociation of Nck from IRE1, though themechanism
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HSP90 can increase IRE1 signalling through interaction with the cytosolic
domains of IRE1. In addition, the cytosolic domains of IRE1may also inter-
act with the pro-apoptotic effector proteins Bax and Bak to promote IRE1
activation, possibly through stabilisation of active IRE1, and it has been
proposed that this forms an interaction platform for pro-apoptotic signal-
ling components [17]. On the other hand, interaction of IRE1 with Bax
Inhibitor-1 reduces IRE1 activity, resulting in protection against ER
stress-induced cell death [18]. Therefore, IRE1 activation is increased by
interaction with pro-apoptotic family members (such as Bax and Bak),
in contrast to the interaction with the pro-survival Bax Inhibitor-1,
which reduces IRE1 activity. Finally, the pro-apoptotic BH3-only proteins
BIM and PUMA have also been proposed to interact with, and promote
the sustained activation of, IRE1 [19]. This suggests a direct mechanism
for interaction between the UPR and the core apoptotic components. Fur-
thermore, the cytosolic kinase and endoribonuclease domains of IRE1 can
be differentially regulated by interacting proteins. For example, IRE1-
dependent JNK activation is thought to be promoted by interaction with
BAK and BIM or PUMA that are artiﬁcially targeted to the ER [20], al-
though whether this applies to wild type versions of these BCL2 proteins
is less clear. In contrast, interaction between IRE1 and HSP72 promotes
XBP1 splicing independently of JNK activation [15]. In addition, inhibition
of IRE1with kinase inhibitors or IRE1-derivedpeptides can promote XBP1
splicing in the absence of RIDD [21,22].
2.2. PERK
PKR-like ER kinase (PERK) was originally identiﬁed as an ER stress-
sensitive eukaryotic initiation factor (eIF) 2α kinase [23,24] and is
required for attenuation of protein synthesis following ER stressPERK PERK
a)
GADD34
GADD34
eIF2
Translation initiation
ATF4
CHOP
PP1
ER lu
B
PERK PERK
P
Fig. 3. Cross-talk between PERK signalling and MAPK pathways. (a) Following ER stress P
oligomerisation,which promotes activation of the cytosolic PERK kinase domain. PERK-depende
to the nucleus and increased transcriptional activity. Nrf2 increases the expression of several an
inhibitory site by PERK, thus attenuating capdependent translation. Due to several short upstre
hibition, and ATF4 promotes the expression of CHOP. CHOP expression is thought to sensitise
promote the expression of GADD34, an activator of protein phosphatase 1 (PP1). PP1 deph
(b) CHOP is also regulated by p38-dependent phosphorylation although it is unclear what r
subsequent activation of CaMKII and the ASK1-MKK4-JNK signalling cascade, leading to cell de(Fig. 3) [25]. PERK is a type-I transmembrane protein with a luminal
N-terminus homologous to IRE1 (around 20% identity between luminal
domains) and a cytosolic C-terminus homologous to the protein kinase
PKR (around 40% identity) [23]. Similar to PKR, the kinase activity of
PERK is stimulated by oligomerisation [26] and requires the autophos-
phorylation of Ser and Thr residues outside of the kinase domain follow-
ing ER stress [27]. PERK phosphorylates and activates nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) in response to ER stress. In un-
stressed cells, Nrf2 is bound to Kelch-like ECH associating protein 1
(Keap1) and is localised within the cytoplasm [28]; however, following
ER stress PERK phosphorylates Nrf2 promoting its dissociation from
Keap1 and allowing Nrf2 to translocate to the nucleus (Fig. 3a)
[28,29]. Nuclear localisation of Nrf2 results in an increase in Nrf2-
dependent transcription of antioxidant response element containing
genes [29]. Indeed Nrf2 activity following ER stress promotes cell sur-
vival and redox homeostasis [30].
In addition to Nrf2, PERK phosphorylates eIF2α on Ser51 to inhibit
the exchange of GDP for GTP within the eIF2 complex [23,24], thereby
inhibiting recruitment of the ribosome to the mRNA bound pre-
initiation complex.Whilst phosphorylation of eIF2α inhibits global pro-
tein translation, it actually promotes translation of mRNAs containing
an internal ribosome entry site (IRES), which does not require
all components of the pre-initiation complex for translation [31].
Many stress-responsive genes encode mRNAs with an IRES within
their 5′ untranslated region and are therefore preferentially translated
following conditions such as ER stress or amino acid starvation [31–33].
Another transcription factor that is activated in response to PERK ac-
tivation is ATF4 [33,34]. ATF4 translation proceeds efﬁciently despite
eIF2α phosphorylation due to a series of short upstream open reading
frames within the 5′ untranslated region [34]; thus ATF4 is activatedb)
CHOP
ER Ca2+ release
CaMKII
JNK
p38
Nrf2
Keap1
Nrf2
men
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ERK is activated by direct interaction with unfolded proteins, dissociation of BiP and
nt phosphorylation of Nrf2 promotes its dissociation fromKeap1, allowing its translocation
tioxidant enzymes which promote cell survival. In addition, eIF2α is phosphorylated at an
am open reading frames, ATF4 is efﬁciently expressed despite PERK-dependent eIF2α in-
cells to ER stress-induced death, and may have a pro-apoptotic role. Both ATF4 and CHOP
osphorylates and reactivates eIF2α, promoting increased cap-dependent translation.
ole this phosphorylation has in response to ER stress. CHOP promotes ER Ca2+ release,
ath.
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phorylation, such as amino acid starvation and oxidative damage.
ATF4 activates a common set of stress response genes and has a role
in promoting adaptation to ER stress by modulating cellular metabolic
activity [35]. One of the components that is expressed in response to
ATF4 activation is the bZIP transcription factor C/EBP homologous pro-
tein (CHOP) (Fig. 3a) [34,36].
2.3. CHOP
CHOP expression is induced in response to a number of cellular
stresses including amino acid starvation [37], genotoxic and mutagenic
agents [38] andER stress [39]. The expression of CHOP alters the compo-
sition of bZIP transcription factor complexes to inhibit transcriptional
activation by CCAAT/enhancer-binding proteins (C/EBP) [40] and re-
lieve transcriptional repression by ATF3 [41]. In addition to forming in-
hibitory heterodimers, CHOP also promotes transcription by targeting
the CHOP-C/EBP complex to a speciﬁc DNA sequence [42].
In many cases CHOP induction is considered to be pro-apoptotic as
CHOP promotes the expression of several apoptotic genes including
the cell surface death receptor 5 (DR5) [43] and the BH3-only proteins
BIM and PUMA [44,45], the latter components of the BCL2 protein
family in the cell intrinsic death pathway. In addition, CHOP induces a
decrease in the expression of the pro-survival protein BCL2 [46]. CHOP
expression can also promote hyperoxidation of the ER lumen through in-
creased expression of ER oxidase 1α (ERO1α) [46–48]. Hyperoxidation of
the ER lumen following ER stress promotes inositol 1,4,5-triphosphate
(IP3)-induced Ca2+ release from the ER lumen due to activation of IP3 re-
ceptor type 1 (IP3R1) [49]. Oxidation of IP3R1 is thought to release it from
a repressive interaction with ERp44, thereby promoting increased IP3R1
activation and release of Ca2+ from the ER lumen, which can promote
cell death [50,51]. Thus CHOP can act indirectly to promote ER stress-
induced release of Ca2+ from the ER lumen and cell death.
However, overexpression of CHOP in the absence of ER stress is not
sufﬁcient to promote cell death in many cell types including mouse em-
bryonic ﬁbroblasts (MEFs), suggesting that additional signalling (such as
ATF4 activation) is required to activate ER stress-induced cell death [52].
Following ER stress, eIF2α phosphorylation attenuates global protein
translation. However, both CHOP and ATF4 promote the expression of
growth arrest and DNA damage 34 (GADD34), an activator of protein
phosphatase 1, which reactivates global mRNA translation by promoting
the dephosphorylation of eIF2α (Fig. 3a) [52–54]. Thismay then promote
cell death due to the further increase in protein load, oxidative stress and
ATP depletion [52]. Although it is unclearwhether CHOP can directly pro-
mote cell death following ER stress, it is clear that expression of CHOP by
the PERK signalling axis sensitises cells to additional cell death signals.
2.4. ATF6
Whilst PERK and IRE1 are functionally homologous ER stress sen-
sors, ATF6 is a unique, constitutively expressed ER stress sensor and
transcription factor present only in mammalian cells [3]. In mammalian
cells, nearly all ER stress responsive genes contain a consensus sequence
(CCAAT-N9-CCACG) within the promoter region (where N is a GC-rich
sequence), which acts as a binding site for several UPR-induced
transcription factors [55,56]. ATF6 was identiﬁed alongside XBP1, as a
bZIP transcription factor that can bind this consensus sequence [56],
promoting the expression of genes that include BiP and CHOP [11,57].
Two isoforms of ATF6 have been identiﬁed; ATF6β is an inefﬁcient tran-
scriptional activator compared to ATF6α, but is a more stable protein
(active ATF6α has a half-life of around 2 h compared to 5 h for active
ATF6β) [58]. In addition, ATF6β can repress the ATF6α-dependent tran-
scription of BiP following ER stress, perhaps due to competition at the
promoter [58]. Therefore, the relative abundance of the two ATF6 iso-
forms appears to modulate ATF6-dependent ER stress signalling [59].
Deletion of ATF6β alone in mice had little impact on UPR-inducedgene expression or cell viability, whereas deletion of ATF6α reduced
the expression of BiP and other UPR-induced genes. However, double
knockout of both isoforms of ATF6 was embryonic lethal, suggesting
that ATF6β can compensate for the loss of ATF6α despite its lower tran-
scriptional activity, and this is sufﬁcient to promote resistance to ER
stress during embryonic development in ATF6α knockout mice [60].
2.5. BiP
BiP, also known as glucose regulated protein 78 (GRP78) is a DnaK-
type, ATP-dependent protein chaperone localised within the ER lumen
where it promotes protein folding [61]. BiP protein has a long half-life
(N48 h) [62] and also has a role in binding ER Ca2+ to buffer around
25% of the luminal Ca2+ load [63]. BiP activity is attenuated by the
post-translational modiﬁcation, ADP ribosylation. This is critical to en-
sure that the ER remains responsive to short-term ﬂuctuations in un-
folded protein load. Levels of unfolded protein within the ER are
inversely correlated to the ADP ribosylation status of BiP, thus ensuring
that BiP activity is attenuatedwhen there is a reduction in unfolded pro-
tein load [64,65]. A reduction in ADP ribosylation of BiP promotes bind-
ing to unfolded proteins and associationwith an activemulti-chaperone
complex [65,66]. UPR activation also results in increased transcription of
BiP through the activity of ATF6 and active XBP1 [9,11]. In this way ER
stress promotes an increase in BiP activity through a combination of
transcriptional and post-translational changes, resulting in increased
ER protein folding capacity.
2.6. UPR activation
The demonstration that BiP binds unfolded proteins within the ER
lumen and that this promotes its dissociation from IRE1, led to the
proposal that the concentration of free BiP was an indicator of ER stress
[1,67]. However in yeast, dissociation from BiP is not required for Ire1 ac-
tivation following ER stress; rather, binding of BiP to the juxtamembrane
region [68] promotes the inactivation of Ire1 following stimulation and
also reduces the sensitivity of Ire1 to ER stress inducers [69]. Furthermore,
the ER luminal domain of Ire1 was subsequently found to bindmisfolded
proteins directly, resulting in Ire1 oligomerisation [70–72]. Mutation of
residues within a hydrophobic groove in the luminal domain of Ire1,
that has a similar structure to the major histocompatibility complex,
abolished binding of Ire1 to a model ER stress-inducing peptide and un-
folded proteins in solution and reduced Ire1 activation [70–72]. In con-
trast, ER stress sensing is not as well characterised in metazoan cells.
The crystal structure of the luminal domain of human IRE1 indicates a
narrower hydrophobic groove compared to that in yeast Ire1 [73]. There-
fore it is unclear whether direct interaction with unfolded proteins is re-
quired for metazoan IRE1 activation, although IRE1 forms higher order
complexes following ER stress [26,74]which in yeast are promoted by in-
teraction of Ire1 with unfolded protein [70–72,75].
Oligomerisation of the luminal domains of IRE1 allows binding of
ATP to the cytosolic domain, inducing the activation of the cytosolic
endoribonuclease/kinase domains of IRE1. Some studies suggest
that IRE1 activation occurs via trans-autophosphorylation after IRE1
dimerisation [76]. An alternative theory is that assembly of IRE1 dimers
into higher order oligomers following nucleotide binding is required for
stabilisation of the endoribonuclease domain [77–79]. IRE1 mutants
that are unable to trans-autophosphorylate retain endoribonuclease ac-
tivity, yet mutants that are unable to bind ATP and ADP do not retain
this activity [80,81]. However, phosphorylation may have a role in
destabilising the higher order IRE1 oligomers [80,82] and may also pro-
mote association of adaptor proteins such as tumour necrosis factor
(TNF) receptor-associated factor (TRAF) 2 with the cytosolic domains of
IRE1 [83]. In summary, IRE1 is thought to be activated by oligomerisation,
which in yeast is promoted in response to the direct interaction of Ire1
with unfolded proteins. In addition, binding of ATP to the cytosolic
domain of IRE1, dissociation of BiP and trans-autophosphorylation also
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of UPR activation and other contributing factors are further discussed by
B. Gardner et al. [75].
PERK is anticipated to have a similar activation mechanism tometa-
zoan IRE1 due to its sequence similaritywithin the core luminal domain
that is crucial for IRE1 activation [70]. Similar to IRE1, active PERK forms
higher order oligomers following ER stress [26], but there is currently no
evidence that direct interaction with unfolded proteins is required for
PERK activation [75]. In contrast to IRE1 and PERK, ATF6 undergoes re-
duction and dissociates intomonomers following ER stress; dissociation
of BiP from the luminal domain of ATF6 uncovers two golgi localisation
sequences and this is required to promote the translocation of ATF6 to
the golgi and its subsequent activation by proteolytic processing
[84,85]. At the golgi membrane, ATF6 is cleaved by the golgi resident
proteases S1P and S2P [86,87]. S1P ﬁrst cleaves the luminal domain of
ATF6, to leave a shortened luminal region adjacent to the golgi mem-
brane. This allows the subsequent cleavage of the transmembrane do-
main of ATF6 by S2P, an intramembrane protease, and release of the
active cytosolic domain of ATF6 (Fig. 4) [88], which translocates to the
nucleus to drive gene transcription.2.7. Pharmacological ER stress inducers
A variety of pharmacological agents are used to induce or mimic ER
stress and have proved valuable in helping to deﬁne the UPR pathways;
however, many of them also activate other signalling events within the
cell so their use does comewith some caveats. The sarco/endoplasmic re-
ticulum Ca2+ ATPase (SERCA) inhibitor, thapsigargin (Tg), is commonly
used when studying ER stress. Tg treatment causes the release of Ca2+
from the ER, thereby undermining the protein folding capacity of the ER
and activating the UPR. However, the increase in cytosolic free Ca2+ aris-
ing from Tg treatment has also been found to activate MAPK signalling
pathways [89] and is likely to induce other signalling pathways. Other
treatments that promote release of Ca2+ from the ER, including the
Ca2+ ionophore A23187 have also been used to induce ER stressATF6 S1P
BiP, CHOP
ATF6p38
S2P
Golgi lumen
P
Cytosol
Nucleus
P P
p38
P P
Fig. 4. Cross-talk between ATF6 signalling and MAPK pathways. Following ER stress, BiP
dissociates from ATF6 uncovering two golgi localisation signals, which promote transloca-
tion of ATF6monomers to the golgi membrane. At the golgi, ATF6 is cleaved by two golgi-
resident proteases, S1P and S2P, releasing the active cytosolic domain. Active ATF6 protein
promotes transcription of ER stress-responsive genes including BiP and CHOP, and its tran-
scriptional activity is modulated by p38-dependent phosphorylation. It is presently un-
clear if p38 phosphorylates ATF6 before it enters the nucleus or, by analogy with other
MAPK pathways, nuclear p38 phosphorylates ATF6 once it has entered the nucleus.but with the same caveat as SERCA inhibitors. Inhibitors of N-linked gly-
cosylation, such as tunicamycin, attenuate protein processing within the
ER and thus promote the accumulation of misfolded protein within the
ER lumen, resulting in ER stress. The disadvantage of this treatment is
that inhibition of the production of a subset of proteins, in this case sub-
strates of N-linked glycosylation, could deplete the components of several
signalling pathways in the cell, thus eliciting changes in signalling path-
ways that are not directly involved in the UPR. The ER stressor brefeldin
A inhibits protein transport from the ER to the golgi thus resulting in ac-
cumulation of proteins within the ER and activation the UPR. The main
disadvantage of this treatment is the subsequent reduction inprotein traf-
ﬁcking to the plasmamembrane, which againmay affect signal transduc-
tion and cell adhesion. Reducing agents such as dithiothreitol can also be
used to induce ER stress throughmanipulation of the ER redox status and
inhibition of disulphide bond formation. This promotes misfolding of
proteins within the ER but also affects redox-dependent signalling
throughout the cell, and particularly within mitochondria. In addition,
redox changeswithin the ER lumenwill be sensedby ER resident proteins
including the IP3R, thus manipulating Ca2+ release and subsequent sig-
nalling alongside UPR activation.
Amino acid analogues, such as the proline analogue azetidine, dis-
rupt protein folding and are often used to induce ER stress. One disad-
vantage of this stressor is that it will also disrupt protein folding in the
cytoplasm resulting in increased expression of cytosolic chaperone pro-
teins and the inhibition of cell growth. ER stress can be more selectively
induced by overexpression of proteins that are prone to misfolding,
such as the human blood clotting factor VIII or amyloid-β derived pep-
tides. Thus although expressing an exogenous sequence can increase
the transcriptional and translational load, low levels of peptide expres-
sion is likely to be a more selective method for inducing ER stress.
Through combined use of these ER stress inducers, it is possible to gen-
erate a robust model of the mammalian UPR.
3. MAPK signalling pathways
The MAPKs are evolutionarily conserved, proline-directed Ser/Thr
protein kinases, distantly related to the cyclin-dependent kinases.
They include extracellular signal-regulated kinases 1 & 2 (ERK1/2),
JNKs and the p38 family and are activated through three-tier kinase sig-
nalling cascades (Fig. 1) [90,91]. The MAPK subgroups are deﬁned in
part by the dual threonine/tyrosinemotif in their activation loop, phos-
phorylation of which is required for their activation: ERK1/2 (Thr-Glu-
Tyr), JNK (Thr-Pro-Tyr), and p38 (Thr-Gly-Tyr) [92–94]. These Thr-X-
Tyr motifs are phosphorylated by select MAP kinase kinases (MKKs),
which are in turn phosphorylated and activated by a number of MAP ki-
nase kinase kinases (MKKKs). The biological outcomes of MAPK signal-
ling are dependent on a variety of factors including the subcellular
localisation of the MAPK (which is determined by scaffold proteins
and determines the repertoire of substrates available), the magnitude
and duration of MAPK activation and combinatorial signalling inputs
provided by other pathways [90].
3.1. ERK1/2
ERK1/2 are activated upon phosphorylation by the dual speciﬁcity
MKKs MAPK or ERK kinase (MEK) 1/2 (Fig. 1) [91]. ERK1/2 were origi-
nally identiﬁed as protein kinases activated in response to stimulation
by extracellular signals such as insulin or nerve growth factor (NGF)
[95,96]. They are now known to be activated following stimulation by
virtually all growth factors including those acting via receptor tyrosine
kinases, receptor serine kinases, cytokine receptors, integrins and
G-protein coupled receptors. MEK1/2 are activated by the RAF protein
kinases (Fig. 1) and this RAF-MEK1/2-ERK1/2 pathway is a major target
for the RAS GTPases, products of the RAS proto-oncogenes.
The duration of ERK1/2 activation determines the outcome of signal-
ling through this pathway in part by regulating the composition of the
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DNA binding and transcriptional activity. Whilst transient ERK1/2 acti-
vation promotes the expression of c-Fos, sustained ERK1/2 activation
is required for the expression of the AP-1 components Fra-1, Fra-2,
c-Jun and JunB and promotes phosphorylation of the C-terminal,
transactivation domain of c-Fos [97–99]. As a consequence, sustained
activation of ERK1/2 in ﬁbroblast cells promotes cyclin D1 expression
and cell proliferation [99]. In contrast, treatment of PC-12 cells with
NGF promotes a very strong and sustained ERK1/2 activation that
leads to cell cycle arrest and terminal differentiation; in this case epider-
mal growth factor stimulates the transient activation of ERK1/2 and fails
to promote differentiation [100].
In addition to control of cell proliferation or differentiation, ERK1/2
activation can clearly promote cell survival in the face of a number of
stress stimuli most notably through the regulation of members of the
BCL2 protein family. For example, ERK1/2 activation promotes the tran-
scription of the pro-survival proteins MCL-1, BCL2 and BCL-XL, most
likely due to activation of the cAMP responsive element binding protein.
In addition, ERK1/2 directly phosphorylates MCL-1 to promote its
stabilisation. ERK1/2 signalling can also promote a decrease in the ex-
pression of several pro-apoptotic proteins including BIM, PUMA and
BMF. For example, ERK1/2-dependent phosphorylation of BIM promotes
its dissociation from the pro-survival proteins BCL-XL andMCL-1 in addi-
tion to promoting its ubiquitination and turnover, whilst phosphorylation
of forkhead box O3 (FOXO3), a transcriptional activator of both BIM
and PUMA, promotes its ubiquitination and degradation, leading to the
ERK1/2-dependent suppression of BIM and PUMA expression [101,102].
Finally, ERK1/2 signalling also promotes the phosphorylation and
proteasome-dependent turnover of BAD. The various mechanisms by
which ERK1/2 signalling can regulate BCL2 proteins to promote cell sur-
vival have been reviewed elsewhere [101,102].
3.2. JNK
The JNKswere initially identiﬁed as kinases that phosphorylated and
activated the transactivation domain of the transcription factor c-Jun in
response to UV treatment of cells [103]. There are three JNK genes
which encode up to ten different JNK isoforms through alternative splic-
ing; both JNK1 and JNK2 are ubiquitously expressed, whilst JNK3 is pri-
marily expressed in the brain [93,104]. The JNK isoforms have different
substrate speciﬁcity as shown by the preferential binding of c-Jun to
JNK1 in comparison to other JNK isoforms [103]. The JNKs are activated
in response to a variety of cellular stresses including UV, ionising radia-
tion,methylating agents, translation inhibitors, heat shock and ER stress
[104]. JNK activation requires dual phosphorylation of the Thr-Pro-Tyr
motif by the upstream kinases MKK4 (which also activates p38)
[105,106] and MKK7 (Fig. 1) [107]. However, the identiﬁcation of alter-
native splice variants of MKK7, which are differentially regulated by
upstream signals, adds to the complexity of JNK regulation [108].
JNK signalling can promote cell death through the de novo expres-
sion of death receptors and their ligands. However, JNK can also target
components of the BCL2 family directly to effect cell death. For example,
under basal (non-stressed) conditions the pro-apoptotic BH3-only pro-
tein, BIM is proposed to be sequestered by binding to the dynein motor
complex; in response to stress, JNK phosphorylates BIM within the dy-
nein light chain binding motif, promoting its release from the dynein
motor complex to initiate apoptosis [109]. In addition JNK phosphory-
lates BCL2 at both Ser and Thr residues to promote cell cycle arrest at
the G2/M-phase reducing the resistance of cells to cell death stimuli
such as paclitaxel treatment [110]. Therefore, JNK activation is generally
thought to be pro-apoptotic. However activation of JNK signalling alone
is not sufﬁcient to promote apoptosis [111] and JNK signalling can also
have a pro-survival role [112]. Furthermore, JNK phosphorylation of
BCL2 at Thr69, Ser70 and Ser87 can promote its dissociation from
Beclin1, thus promoting autophagy [113] and potentially promoting
cell survival.3.3. p38
The p38 MAPKs were originally identiﬁed as proteins activated in
response to cellular stresses such as hyperosmolarity, arsenite or taxol
and pro-inﬂammatory cytokines [92,114]. They require dual phosphor-
ylation of a Thr-Gly-Tyr motif for activation [105] and this is catalysed
by MKK3, MKK4 and MKK6 but not MEK1/2 signalling (Fig. 1)
[105,106,115]. There are four proteins in the p38 family; p38α and
p38β are ubiquitously expressed, whereas p38γ and p38δ exhibit a
more limited tissue distribution and have different substrate speciﬁc-
ities compared to the more widely expressed family members [90].
Activation of p38 can either promote cell proliferation or induce cell
cycle arrest, depending on the kinetics of activation and downstream
signalling pathways activated. Following growth factor stimulation,
p38 undergoes transient activation which induces cyclin D1 expression
and phosphorylation of the transcriptional repressor, retinoblastoma-
associated protein (Rb) [116]. Phosphorylation of Rb promotes its disso-
ciation from E2F and increased transcription of S-phase entry genes
therefore inducing cell proliferation [117]. In contrast, prolonged activa-
tion of p38, as is seen in response to cellular stresses such as anisomycin,
arsenite or tunicamycin [116,118,119], leads to the activation of MAPK-
activated protein kinase-2 (MK-2) and its substrate cAMP-responsive
element-binding protein [116]. This promotes cell cycle arrest, perhaps
through induction of the cyclin-dependent kinase (CDK) inhibitors p16,
p21 or p27 [119–121]. In addition to cell cycle regulation, p38 activation
can also promote cell death through phosphorylation of BIMat the same
site as JNK [122] aswell as promoting the expression of BIM through ac-
tivation of the transcription factor FOXO3a [123]. Furthermore, p38-
dependent phosphorylation of the transcriptional activator p53 pro-
motes its stabilisation and transcriptional activity. The subsequent in-
crease in apoptosis is likely to be due to the increased expression of
p53-target genes, which includes expression of the pro-apoptotic pro-
teins PUMA and NOXA [124].
4. ER stress and MAPKs
All three of the canonical MAPKs (ERK1/2, JNK and p38) are known
to be activated in response to ER stress, eachwith different kinetics and
with different roles [125,126]. Generally, ERK1/2 activation is consid-
ered to promote cell survival, but to what extent this protective role ex-
tends to ER stress is unclear. By analogywith its role in proliferation and
differentiation, the role of ERK1/2 activation in ER stress signalling is
likely to be determined by the kinetics of its activation, which will de-
pend on the nature of the ER stress stimulus. In addition, ER stress in-
duces an increase in both JNK and p38 activation [126], suggesting
that these MAPKs may have a role in the response to ER stress [125].
Furthermore, ER stress-induced JNK activation is higher in hepatocytes
derived from aged rat compared to their younger counterparts and re-
sults in greater cell death [126], suggesting a role for JNK signalling in
ER stress-induced cell death. In some cell lines, inhibition of JNK reduces
UPR activation, suggesting that JNK signalling can promote ER stress
through an unidentiﬁed mechanism, leading to ER stress-induced cell
death [127,128]. Therefore JNK signalling can increase ER stress and is
also activated as a consequence of the UPR. Below we review the inter-
play between the UPR and MAPK signalling components and how this
may contribute to cell survival or cell death decisions.
5. IRE1 and MAPK signalling
5.1. IRE1 activates JNK to promote cell death
In a variety of cell lines, ER stress has been found to induce JNK acti-
vation and this is thought to initiate a pro-apoptotic response.Whilst ER
stress promotes the oligomerisation of IRE1 and its activation, IRE1 acti-
vation can be enforced through its overexpression, allowing activation
of IRE1 in the absence of ER stress. This activation of IRE1 is sufﬁcient
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but not the endoribonuclease domain. The adaptor protein TRAF2 was
found to bind to IRE1 through a yeast two-hybrid screen. Following ER
stress, IRE1 oligomerises, activating its kinase domain. This interacts
with TRAF2 via its C-terminal TRAF domain promoting the clustering
of the N-terminal effector domain of TRAF2 [83]. More recently, the
IRE1-TRAF2 dependent activation of JNK following ER stress was
found to require the MKKK apoptosis signal-regulating kinase 1
(ASK1). In support of this, MEFs and primary neurons from ASK1−/−
mice showed a reduction in ER stress-induced JNK activation and
were more resistant to ER stress-induced apoptosis [129]. Interaction
with IRE1-TRAF2 promotes ASK1 oligomerisation [130] and induces a
conformational change to promote intermolecular autophosphorylation
of Thr845within the ASK1 activation loop. Phosphorylation of Thr845 is
required for the kinase activity of ASK1 and its subsequent activation of
JNK signalling [131]. ASK1 has been shown to phosphorylate and acti-
vate MKK4/MKK7 and MKK3/MKK6, the upstream kinases for JNK and
p38 respectively (Fig. 1) [132].
Aside from activation by TRAF2, ASK1 is regulated by interaction
with a network of kinases and phosphatases in addition to binding pro-
teins such as 14-3-3 [133]. Phosphorylation of ASK1 on Ser83 by the
pro-survival protein kinases PIM1 or the Ak mouse thymoma oncogene
(Akt, also known as protein kinase B) decreases ASK1 activity leading to
a reduction in JNK activation and reduced sensitivity to stress-induced
apoptosis [134,135]. ASK1 is inactivated by dephosphorylation of
Thr845 and this may occur through protein phosphatase 5 activity,
which binds to ASK1 in response to oxidative stress [136]. Furthermore,
ASK1 dephosphorylation on Ser967 is required for dissociation from14-
3-3 and activation in response to stress [137]. It is currently unclear how
this network of ASK1 regulators and binding proteins are co-ordinated
in response to ER stress to promote ASK1 activation and subsequent
JNK activation. However, oligomerisation of IRE1 forms a platform to
promote signalling via TRAF2 and ASK1, leading to JNK activation fol-
lowing ER stress (Fig. 2c).
Intriguingly, whilst in most cases the IRE1-dependent activation of
JNK is considered to be pro-apoptotic [129,134,135], inhibition of JNK2
activation in a human lymphoblast cell line (U937 cells) promoted cell
death by apoptosis following ER stress. JNK2 activation was required
for progression of autophagy and a reduction of unfolded protein load
in the ER. Thus activation of JNK2 following ER stress promoted cell sur-
vival in these cells [138].5.2. IRE1-dependent c-Jun activation inhibits ER stress-induced death
The transactivation domain of the transcription factor and proto-
oncogene c-Jun is phosphorylated by JNK and this promotes c-Jun acti-
vation [103]. As a bZIP transcription factor, c-Jun can form both hetero-
and homodimers as part of AP-1 transcription factor complexes [139].
Phosphorylation of both JNK and c-Jun increases following ER stress,
and c-Jun is required for the transcription of Adapt78 in response to
ER stress [140]. Adapt78 is an inhibitor of the Ca2+-responsive protein
phosphatase, calcineurin and so can act to decrease calcineurin activity
following ER stress [140]. ER stress promotes the cleavage and activa-
tion of an ER-associated caspase, caspase 12 in rodents or caspase 4 in
human cells (murine caspase 12 has 48% sequence identity to human
caspase 4); this can contribute to ER stress-induced apoptosis
[141,142]. Expression of c-Junwas shown to reduce caspase 12 cleavage
and protect cells against Tg-induced cell death, although it is unclear
whether the increased expression of Adapt78 and calcineurin inhibition
has a role in this response [140]. In addition, calcineurin is activated
by caspase-dependent cleavage and inhibition of calcineurin can at-
tenuate Tg-induced apoptosis [143]; this suggests that calcineurin
can promote ER stress-induced cell death, but may act downstream
of caspase 12. Therefore, whilst JNK activation is implicated in pro-
moting ER stress-induced apoptosis, it can also act to reduce ERstress-induced apoptosis through Adapt78 transcription and cal-
cineurin inhibition (Fig. 2c).
5.3. IRE1-dependent ERK1/2 activation promotes survival
ERK1/2 activation is partially IRE1-dependent in MEFs treated with
the proline analogue azetidine-2 carboxylic acid as an ER stress inducer
and has also been re-capitulated in a cell-free ER stress assay in vitro. In
this assay, depletion of the adaptor protein, Nck, from the system result-
ed in a reduction in ER stress-induced ERK1/2 activation. Nckwas found
to associate at the ER membrane with the cytosolic domain of IRE1 via
its SH3 domains. At the ER membrane Nck inhibited ERK1/2 activation,
whereas dissociation of Nck from the ER membrane following ER stress
promoted the increased activation of ERK1/2 and correlated in vivowith
increased cell proliferation and reduced apoptosis [144]. Thus whilst ER
localised Nck interacts with inactive IRE1 and this inhibits ERK1/2 acti-
vation, dissociation of Nck from active IRE1 and the ER membrane pro-
motes the cytosolic localisation of Nck and IRE1-dependent ERK1/2
activation (Fig. 2c). This suggests that activation of IRE1 promotes a con-
formational change within the cytosolic domains to promote both Nck
dissociation from IRE1 and the subsequent activation of ERK1/2. How-
ever, it remains unclear how ERK1/2 is activated and if a direct interac-
tion with either Nck or IRE1 is required as it is more likely that an
upstream MKK is also necessary for ERK1/2 activation.
ER stress-induced ERK1/2 activation has also been shown to be par-
tially IRE1-dependent in gastric cancer cells, as siRNA knockdown of
IRE1 attenuated ERK1/2 activation following ER stress. In these cells, in-
hibition of ERK1/2 signalling promoted ER stress-induced apoptosis,
perhaps through a reduction in BiP levels. ERK1/2 inhibition attenuated
the ER stress-induced increase in BiP mRNA and protein levels and the
reduction in BiP levels was sufﬁcient to promote ER stress-induced
apoptosis [145]. Thus signalling through the IRE1 axis of the UPR
can promote activation of ERK1/2, which may have a pro-survival
role following ER stress. However, in neither case is it clear how
ERK1/2 signalling acts to promote cell survival during ER stress
and how this relates to reports that ER stress initiates apoptosis by
activating BIM or PUMA.
6. The PERK-CHOP signalling axis and MAPKs
6.1. p38-dependent phosphorylation of CHOP is required for CHOP
activation
CHOP contains two serines within a favourable sequence context for
MAPK phosphorylation. Mutation of Ser78 or Ser81 to alanine reduced
the proportion of stress-induced CHOP phosphorylation, whilst the
double mutation abolished phosphorylation. These sites were found to
be phosphorylated by p38, but not by ERK2 or JNK3 both in an in vitro
kinase assay and in a cell line overexpressing CHOP (Fig. 3b) [118]. Al-
though phosphorylation of CHOP appeared to have no effect on its
DNA binding activity or its dimerisation speciﬁcity, results from a
transactivation domain reporter construct suggested that phosphoryla-
tion by p38 increases the activity of the CHOP transactivation domain
[118]. This may have important implications for other C/EBP family pro-
teins such as C/EBPβ, which are also phosphorylated by MAPKs [146].
MAPK signalling may alter the activity of a CHOP-C/EBP dimer through
phosphorylation of either or both proteins in the complex and sub-
sequent modiﬁcation of transactivation domain activity. In vivo,
p38-dependent phosphorylation of CHOP was required to inhibit
differentiation of a pre-adipose cell line [118]. In addition, p38-
dependent phosphorylation of CHOP was also required for maximal
cell death in response to CHOP overexpression in HeLa cells [147].
Therefore, it seems likely that p38-dependent phosphorylation of
CHOP alters both the activity of the transactivation domain and sub-
sequently its afﬁnity for binding partners, leading to an altered gene
expression proﬁle. However it is currently not known which genes
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the altered cell phenotypes.
6.2. JNK is a downstream effector of the CHOP-CaMKII pathway
CHOP expression can promote the ER stress-induced release of Ca2+
due to hyperoxidation of the ER lumen and increased activation of IP3R1
(Section 2.3). In macrophages, the ER stress-induced release of Ca2+
from the ER lumen results in the transient activation of Ca2+/
calmodulin-dependent protein kinase II (CaMKII) [148]. This protein is
then able to autophosphorylate on Thr287 and is further activated by
ER stress-induced reactive oxygen species production, through oxida-
tion of Met281/282 [148,149], which leads to sustained CaMKII activa-
tion, which can promote apoptosis through at least two pathways.
Firstly, CaMKII is translocated to the surface of mitochondria, which
leads to an accumulation of Ca2+ within mitochondria. Although the
mechanism for this hasn't been identiﬁed, mitochondrial localised
CaMKII may promote signalling to mitochondrial Ca2+ transporters or
may promote increased ER-mitochondria contacts and thus greater
ER-mitochondria Ca2+ transport. Increased mitochondrial Ca2+ uptake
promotes loss of mitochondrial membrane potential allowing cyto-
chrome c release and apoptosis. Secondly, CaMKII promotes JNK signal-
ling, through activation of the MKKKs ASK1 [150] or TAK1 [151] and
subsequent MKK4 activation (Fig. 3b). CaMKII-dependent JNK activa-
tion promoted a subsequent increase in Fas (a death receptor) expres-
sion and consequently an increase in the cell surface localisation of Fas
[148]. In vivo, the knockout of CaMKII in mice reduced ER stress-
induced apoptosis inmacrophages, spleen and renal tubular epithelium.
Renal function was maintained despite tunicamycin treatment in the
CaMKII knockout mice [148], showing that ER stress-induced CaMKII
activation is required for cell death. Therefore, in addition to activation
by the IRE1-TRAF2-ASK1 pathway, JNK is also activated in response to
CaMKII signalling. However, it is unclear whether the PERK-CHOP axis
of the UPR has a role in the ER stress-induced Ca2+ release and CaMKII
activation.
7. ATF6 and MAPK signalling
7.1. p38 phosphorylates ATF6 increasing its transcriptional activity
In atrial cardiomyocytes, growth factor stimulation promotes the
p38-dependent expression of atrial natriuretic factor (ANF). Intriguing-
ly, the promoter region for ANF does not contain a binding site for the
previously recognised p38-inducible transcription factors, but can be
activated by ATF6. Analysis of ATF6 showed that it can undergo phos-
phorylation and was a substrate for p38 in vitro. Furthermore, transfec-
tion of primary myocardial cells with ATF6 and p38α, promoted the
transactivation activity of ATF6 in a luciferase reporter assay [152].
Sustained p38 activation resulted in increased ATF6 phosphorylation
and promoted the activity of the transactivation domain of ATF6 at the
BiP promoter (Fig. 4). Interestingly, following Tg treatment, induction
of BiP expression occurred independently of p38 activation. On the
other hand, p38 signalling was required for induction of BiP transcrip-
tion in response to the ER stress inducer and proline analogue azetidine
[153]. This suggests variation in the use of p38 depending on the ER
stress inducer; whether this reﬂects the contributions made by other
pathways activated by these various ER stressors is unclear.
8. ER stress and MAPK signalling in disease
ER stress and the resultant activation of signalling pathways arising
from this has a key role in many diseases including neurodegeneration
[154] and various cancer types [155]. In some cases, MAPK signalling
has been identiﬁed as interactingwith the ER stress response in speciﬁc
disease models, as highlighted below.8.1. Cell surface BiP and ERK1/2 activation
The protein chaperone BiP is ubiquitously expressed but its expres-
sion is increased following ER stress. Newly synthesised BiP has been
found to translocate to the external surface of the plasma membrane
perhaps due to association with DnaJ family members [156]. BiP on
the cell surface of colon cancer, neuroblastoma and leukaemia cells
[157] interacts with many proteins and may initiate RAF-MEK1/2-
ERK1/2 signalling to promote tumour cell survival [158]. Indeed detec-
tion of over expressed or cell surface BiP has been proposed as a poten-
tial diagnostic marker in hepatocellular carcinoma and other cancers
due to the detection of autoantibodies against BiP in patient samples
[159].8.2. ER stress and ERK1/2 signalling in cancer
Around 50% ofmelanomas contain an activating BRAFV600Emutation
and exhibit hyperactivation of ERK1/2 and addiction to this pathway;
therefore the generation of therapeutics that target the mutant kinase
are of considerable interest. Vemurafenib is a BRAFV600E speciﬁc inhibi-
tor that is effective in treatingmelanoma patients although acquired re-
sistance to vemurafenib is a common problem. Interestingly, treatment
with vemurafenib has been found to promote the release of Ca2+ from
the ER inmelanoma cells, thereby activating the UPR [160]. Knockdown
of ATF4 reduced apoptosis arising from vemurafenib treatment, sug-
gesting that vemurafenib promotes ER stress-induced apoptosis. How-
ever, melanoma cells with acquired resistance to vemurafenib were
still sensitive to Tg-induced cell death implying only partial overlap be-
tween the mechanism of apoptosis induction with these treatments
[160]. Further support for the combined use of ERK1/2 signalling path-
way inhibitors and ER stressors comes from the ﬁnding that whilst
some human melanoma cell lines are relatively insensitive to ER
stress-induced or MEK1/2 inhibitor-induced cell death, treatment of
these cells with a MEK1/2 inhibitor or with MEK1 targeted siRNA
sensitised the cells to ER stress-induced apoptosis [161]. The mecha-
nism for this varied between the melanoma cell lines. In some cases
MEK1/2 inhibition resulted in a reduction in both BiPmRNA and protein
levels. Caspase 4 is localised on the ERmembrane and is cleaved and ac-
tivated in response to treatment with ER stress inducers [142]. Inhibi-
tion of MEK1/2 promoted release of caspase 4 from BiP and so
promoted its activation. The subsequent activation of caspase 4 required
stimulation by an ER stressor, as MEK1/2 inhibition and addition of BiP
siRNA was insufﬁcient to promote cell death [161]. Therefore ERK1/2
activation protects melanoma cells against ER stress-induced cell
death through increased BiP expression and inhibition of caspase 4
activation.
Another mechanism by which ERK1/2 activation may protect
against ER stress-induced cell death is the ERK1/2-dependent up-
regulation of MCL-1, a pro-survival BCL2 protein. The activation of
IRE1 and ATF6 in melanoma cells following ER stress promoted the
up-regulation of MCL-1 mRNA and protein, and this was partially
blocked by inhibitors of ERK1/2 signalling. Following ER stress MCL-1
can bind to and neutralise the pro-apoptotic proteins PUMA and
NOXA, preventing apoptosis, whereas loss of MCL-1 releases PUMA
and NOXA (which are also up-regulated by ER stress), thereby
sensitising cells to ER stress-induced apoptosis [162].
In support of a role for ERK1/2 activation in the resistance ofmelano-
ma cells to ER stress, a recent study investigated the effect of oncogenic
BRAFV600E overexpression and increased ERK1/2 activation in melano-
cytes. Activation of ERK1/2 was found to promote the phosphorylation
of eIF4E and thus induce an increase in protein synthesis in addition
to increased IRE1 and ATF6 signalling. This suggests that acquisition of
oncogenic BRAFV600E causes chronic ER stress. Survival and adaptation
of cells to this chronic ER stress appear to be one of the changes required
to promote melanoma pathogenesis [163].
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ment induced ER stress via release of Ca2+ from the ER and reduced
protein folding capacity [160] but that overexpression of BRAFV600E
also induced ER stress through increased protein load [163]. This indi-
cates that contradictory changes to the cellular signalling network can
perturb ER homeostasis resulting in ER stress. Indeed, manipulation of
ER homeostasis has obvious therapeutic potential, particularly in com-
bination with ERK1/2 inhibition in melanoma cells. However there is
also the challenge that ER homeostasis can be unbalanced as an unantic-
ipated consequence of cell treatment in both experimental and thera-
peutic settings.
In addition to melanoma cells, ERK1/2 activation also reduced ER
stress-induced cell death in hepatocellular carcinoma cells where it
acted alongside Akt signalling to promote cell cycle arrest following
ER stress. Interestingly ER stress-induced Akt activation was inversely
correlated to ERK1/2 activation suggesting cross-talk between these sig-
nalling pathways in the response to ER stress. This is likely due to the
Akt-dependent inhibitory phosphorylation of the MKKK c-RAF on
Ser259 and thus a reduction in ERK1/2 activation. However, after
around 3 h of Tg or tunicamycin treatment there was a reduction in
Akt activation and a subsequent increase in ERK1/2 activation in hepa-
tocellular carcinoma cells. Although activation of either Akt or ERK1/2
signalling appeared to promote cell cycle arrest following ER stress,
ERK1/2 activation was a more potent inhibitor of ER stress-induced
cell death in hepatocellular carcinoma cells [164]. ER stress-induced
loss of cyclin D1 was required for cell cycle arrest [164] but it is unclear
how ERK1/2 signallingmay contribute to this cell cycle arrest, especially
as sustained ERK1/2 activation promotes cyclin D1 expression and cell
cycle progression inﬁbroblast cells [99]. However, concurrent activation
of the UPR will alter the context for ERK1/2 signalling and this may ac-
count for the contribution of sustained ERK1/2 signalling to ER stress-
induced cell cycle arrest in hepatocellular carcinoma cells. Both the
ERK1/2 and Akt signalling pathways also protected against ER stress in-
duced cell death in human lung (H1299) and breast (Mcf-7) cancer cell
lines [165]. However, Akt inhibition resulted in a greater increase in ER
stress-induced cell death than ERK1/2 inhibition in these cell lines, due
to the Akt-dependent increase in the pro-survival proteins c-IAP-2 and
XIAPwhich inhibit ER stress-induced caspase activation [165]. Thus it is
clear that ERK1/2 activation protects against ER stress-induced cell
death through cell cycle arrest, up-regulation of pro-survival proteins
including MCL-1 and/or increased BiP expression in a variety of human
tumour cell lines.
On the other hand, other cancer cell lines show an ERK1/2-
dependent increase in ER stress-induced cell death. In the human neu-
roblastoma cell line, SH-SY5Y, inhibition of ERK1/2 activation reduced
Tg-induced cell death as judged by cell lysis and lactate dehydrogenase
release. This effect was also seen in response to alternative ER stressors
and suggested that ERK1/2 activation might promote ER stress-induced
cell death in SH-SY5Y cells. Intriguingly, ERK1/2 inhibition had no effect
on the proportion of cells with apoptotic markers, including DNA
laddering, caspase 3 activation and poly ADP-ribose polymerase cleav-
age. This suggests that ER stress-induced ERK1/2 activation may pro-
mote either caspase-independent cell death or could act downstream
of caspases to promote cell death [166]. The mechanism for cell death
induced by ERK1/2 activation following ER stress is yet to be identiﬁed;
however, ERK1/2 activation has also been shown to promote ER stress-
induced cell death in the colorectal cancer cell line, HCT116. In these
cells, Tg-induced cell death was caspase 8-dependent and activation of
caspase 8 was in turn partially dependent on CHOP-induced DR5 expres-
sion [43,167]. Although ERK2 activation was found to promote Tg-
induced cell death inHCT116 cells themechanism for this cell death is un-
clear as PUMA, NOXA and BAD are reported to have a role in this cell
death [167] but in most cases are repressed by ERK1/2 signalling
[101,102].
The role of ERK1/2 activation in promoting ER stress-induced cell
death in the colorectal cancer cell line HCT116 [167] and theneuroblastoma cell line SH-SY5Y [166] is in contrast to melanoma,
breast cancer and a number of other cancer cell lines, where ERK1/2 ac-
tivation has been shown to protect against ER stress-induced apoptosis
[161,165].
8.3. Retinal degeneration in Drosophila
Activation of ER stress signalling has been identiﬁed inmany degen-
erative diseases including human age-related retinal degenerative
disease (retinitis pigmentosa), which is caused by the expression ofmu-
tant rhodopsin proteins. The expression of a similar mutant rhodopsin-1
allele inDrosophila can be used tomodel this disease andwas found to ac-
tivate ER stress-induced apoptosis. The ER stress-induced cell death
caused by expression of mutant Rhodopsin-1 was attenuated by the
knockdownof CDK5 orMEKK1 [168]. CDK5has been shown to be activat-
ed by avariety of stresses and increased activation of CDK5promotes neu-
rodegeneration in models for Alzheimer's [169] and Parkinson's [170]
disease. When the UPR was interrogated, CDK5 activation did not affect
the activation of ATF4 or splicing of XBP1, and may act downstream of
UPR activation. Although the mechanism for ER stress-induced CDK5 ac-
tivation is unclear, knockdown of CDK5 or MEKK1 was able to delay late
onset retinal degeneration in a Drosophilamodel [168]. CDK5 is able to
bind andphosphorylateMEKK1, resulting in its activation and subsequent
JNK activation suggesting that JNK might be responsible for ER stress-
induced CDK5-dependent cell death.
8.4. Atherosclerosis
The development of atherosclerotic lesions is associatedwith the re-
cruitment ofmonocytes to the sub-endothelial space, which then differ-
entiate into macrophages. Macrophages internalise cholesterol-rich
lipoprotein and this is esteriﬁed and stored as cholesteryl-fatty acid es-
ters [171]. Advanced lesions commonly show a build-up of unesteriﬁed
cholesterol, which has been found to activate the UPR and can lead to
apoptosis [172]. A common atherosclerosis model that involves the
loading of macrophages with unesteriﬁed cholesterol induced a p38-
dependent increase in CHOP, whereas other forms of ER stress induc-
tion, such as Tg or tunicamycin treatment result in p38-independent
CHOP induction. In this model for atherosclerosis, activation of three
pathways was required for induction of apoptosis; ER stress-induced
JNK and p38 pathway activation, which subsequently led to CHOP in-
duction and thirdly, activation of signalling downstream of the Scaven-
ger Receptor Type A (also known as CD204) was required [173]. The
signalling involved in CD204-induced cell death has not been clearly
identiﬁed butmay involve inhibition of PI3K-Akt or β-catenin signalling
[174]. Further to the activation of JNK and p38 signalling, cholesterol
trafﬁcking to the ER inmacrophages promoted the production of the in-
ﬂammatory cytokines TNFα and interleukin-6 (IL-6). The increase in
TNFα mRNA was CHOP-independent, but required the activation of
p38 and JNK. In contrast, loss of CHOP reduced ERK1/2 activation and
subsequent IL-6 production following free cholesterol stimulation
[175]. This suggests a possible link between partially p38-dependent
CHOP induction and ERK1/2 activation in macrophages.
8.5. Diabetes and JNK activation
In mouse models for obesity, liver and adipose tissue samples were
found to have increased ER stress signalling and JNK activation. Further-
more, treatment of murine liver cells with an ER stressor decreased
insulin-induced signalling, suggesting a possible link between ER stress,
obesity and insulin sensitivity. Insulin is an activating ligand of both the
insulin and insulin-like growth factor-1 receptors, which are both re-
ceptor tyrosine kinases. Activation of these receptors promotes binding
and tyrosine phosphorylation of insulin receptor substrate 1 (IRS1)
which initiates downstream signalling. Treatment of murine liver cells
with an ER stressor promoted IRE1 activation and subsequent JNK
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Ser312 on human IRS1) by JNK, which inhibits insulin-induced tyrosine
phosphorylation of IRS1 and downstream signalling [177]. This clearly
demonstrates a link between ER stress, JNK activation and insulin sensi-
tivity. Indeed,mice that are heterozygous for the presence of XBP1 dem-
onstrate higher levels of ER stress signalling, reduced sensitivity to
insulin and were pre-disposed to develop type II diabetes [176]. More-
over, chemical chaperones such as 4-phenyl butyric acid that improve
the folding capacity of the ER have been demonstrated to reduce UPR
signalling inmouse obesity models and lower blood insulin and glucose
levels closer to those inwild typemice. Indeed, markers for both obesity
and type II diabetes are normalised in mouse models of obesity treated
with chemical chaperones that reduce ER stress signalling [178]. Thus in
mouse, high levels of UPR signalling and subsequent JNK activation pro-
mote reduced sensitivity to insulin and the development of type II
diabetes.
8.6. ER stress pre-conditioning in ischemia
Inmodels of ischemiawithin the kidney, activation of ERK1/2 signal-
ling or inhibition of JNK protected against cell death due to oxidative
stress [179]. Activation of the UPR has been identiﬁed during ische-
mia/reperfusion injury within the brain, heart and kidney [180]. In
the post-ischemic kidney, cells were protected against subsequent
ischemia-induced injury for up to 15 days and this was associated
with loss of JNK and p38 signalling [181]. In a model for this transient
ischemia-induced protection, renal epithelial cells were pre-conditioned
by ER stress, which protected these cells against subsequent oxidative
stress. The ER stress pre-conditioned cells showed greater activation of
ERK1/2 signalling and a reduction in JNK activation following oxidative
stress. This suggests that pre-conditioning cells by activation of the UPR
modulates the balance of signalling through different MAPK pathways
to promote cell survival following subsequent oxidative stress [179].
The mechanism for this ‘cellular memory’ effect is not currently known
but likely reﬂects changes in the expression of genes controlling detoxiﬁ-
cation, damage repair or cell death.
9. Conclusions and future challenges
There are clearly strong links between the UPR andMAPK signalling
networks. In some cases UPR signalling feeds into MAPK activation so
that theMAPKs act as effector pathways; in addition, a number of inter-
action points allow cross-talk between these pathways. Activation of
the UPR promotes IRE1-dependent ERK1/2 activation and JNK activa-
tion through IRE1-TRAF2-ASK1 signalling or due to ER stress-induced
Ca2+ release. In addition, MAPK signalling can modulate the UPR
through p38-dependent phosphorylation of CHOP and ATF6. In general,
ERK1/2 activation is thought to promote cell survival whereas JNK and
p38 signalling are considered pro-apoptotic. However, there are several
exceptions to this; for example, IRE1-dependent JNK signalling pro-
motes c-Jun activity and expression of the pro-survival protein
Adapt78. In addition, although there are many cases where ERK1/2 sig-
nalling protects against ER stress-induced cell death (such as inmelano-
ma or hepatocellular carcinoma), there are several cases where the
opposite applies (including the colorectal cancer cell line, HCT116, or
the neuroblastoma cell line SH-SY5Y). What determines whether
MAPK-dependent signalling promotes cell proliferation, survival or
cell death is unclear but by analogy with other studies the response to
ER stress probably reﬂects differences in signal duration, signal magni-
tude, coincident signalling events and cell type-speciﬁc expression of
MAPK effectors.
Although there are still several challenges in understanding the role
ofMAPK signalling and ER stress in some diseases, there are caseswhere
there are indications that therapeutics to manipulate both UPR and
MAPK signalling could be advantageous. For example, some melanoma
lines are relatively insensitive to treatment with inhibitors of ERK1/2activation or ER stressors individually but their combined use promoted
ER stress-induced cell death [161]. Indeed, cells that were resistant to
the BRAFV600E inhibitor vemurafenib were still sensitive to ER stress-
induced cell death [160], again indicating that combining ERK1/2 path-
way inhibitors and ER stressors should be investigated. On the other
hand, JNK inhibition may promote protection against ER stress-
induced cell death in retinal degeneration, ischemia and atherosclerosis.
In addition, JNK inhibition and increased ER protein folding capacity due
to chaperone expression could reduce inﬂammatory cytokine produc-
tion in atherosclerosis. Furthermore, a reduction in ER stress signalling
normalised obesity and type II diabetes markers in mice [178] suggest-
ing potential for similar treatments in human cells. Whilst inhibitors of
MAPK pathways are already well characterised and undergoing clinical
evaluation, the UPR ﬁeld has lagged behind in terms of drug discovery
and potent and selective agents targeting the UPR components are rel-
atively few. However, the recent description of a selective PERK inhibi-
tor [182] and the emergence of a number of IRE1 inhibitors [183] should
pave the way towards a greater understanding of the roles of PERK and
IRE1 in disease.
However, the biggest challenge in developing treatments that ma-
nipulate UPR signalling or ER homeostasis in disease is avoiding off-
target affects. Without targeting the ER stressor or UPR inhibitor to a
subset of cells, off-target changes to ER homeostasis are likely to partic-
ularly affect secretory cells including insulin-producing pancreatic β
cells and antibody-secreting B lymphocytes, due to the acute ER stress
involved in these processes. In addition, understanding the mechanism
of ER stress-induced cell death in different cells and how MAPK signal-
ling interacts with this may provide further insight into the variation in
response to ERK1/2 activation seen in different cancer cell types, in ad-
dition to highlighting further candidates for therapeutic intervention.Acknowledgements
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